Safety and tolerability of antipsychotics: Focus on amisulpride

Drug, Healthcare and Patient Safety

Volumn 2, Issue 1, 2010, Pages 205-211

  Juruena, Mario F ^a   de Sena, Eduardo Pondé ^b   de Oliveira, Irismar Reis ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

Author keywords

Adverse events; Amisulpride; Antipsychotic agents; Safety; Tolerability

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ASENUPINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN 7 RECEPTOR; SEROTONIN ANTAGONIST; SERTINDOLE; UNCLASSIFIED DRUG; ZIPRASIDONE;

AGRANULOCYTOSIS; AKATHISIA; ANTICHOLINERGIC EFFECT; ANTIDEPRESSANT ACTIVITY; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DOPAMINE RECEPTOR BLOCKING; DOPAMINERGIC TRANSMISSION; DRUG ACTIVITY; DRUG CHOICE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPERPROLACTINEMIA; HYPERSALIVATION; INSULIN RESISTANCE; METABOLIC DISORDER; MOTOR DYSFUNCTION; NEGATIVE SYNDROME; NEUROLEPTIC MALIGNANT SYNDROME; OBESITY; ORTHOSTATIC HYPOTENSION; PATIENT SATISFACTION; POSITIVE SYNDROME; PULSE RATE; QT PROLONGATION; QUALITY OF LIFE; RECEPTOR AFFINITY; REVIEW; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL INTERACTION; TARDIVE DYSKINESIA; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; XEROSTOMIA;

EID: 78650716710     PISSN: None     EISSN: 11791365     Source Type: Journal    
DOI: 10.2147/DHPS.S6226     Document Type: Review

References (51)

1. Lahti AC, Weiler MA, Holcomb HH, Tamminga CA, Carpenter WT, McMahon R. Correlations between rCBF and symptoms in two independent cohorts of drug-free patients with schizophrenia. Neuropsychopharmacology. 2006;31:221-230.
2. Meltzer HY. What's atypical about atypical antipsychotic drugs? Curr Opin Pharmacol. 2004;4:53-57.
3. Robertson GS, Matsumura H, Fibiger HC. Induction patterns of fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther. 1994;271:1058-1066.
4. de Oliveira IR, Ribeiro MG, Fregoneze JB, de Sena EP, de Castro E, Silva E. Regional c-fos expression in rat brain may predict antipsychotic therapeutic window. J Clin Psychopharmacol. 2000;20:705-706.
5. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis. BMJ. 2000;321:1371-1376.
6. Kapur S. Psychosis as a state of aberrant salience: A framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry. 2003;160:13-23.
7. Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology. 1999;21:106-115.
8. Schoemaker H, Claustre Y, Fage D, et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther. 1997;280:83-97.
9. Leucht S, Pitschel-Walz G, Engel RR, Kissling W. Amisulpride, an unusual "atypical" antipsychotic: A meta-analysis of randomized controlled trials. Am J Psychiatry. 2002;159:180-190.
10. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;6:553-564.
11. de Oliveira IR, Miranda-Scippa AM, de Sena EP, et al. Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety. J Clin Pharm Ther. 1996;21:349-358.
12. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Secondgeneration versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis. Lancet. 2009;373:31-41.
13. Wetzel H, Grunder G, Hillert A, et al. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology - a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group. Psychopharmacology (Berl). 1998;137:223-232.
14. Sleight AJ, Carolo C, Petit N, Zwingelstein C, Bourson A. Identification of 5-hydroxytryptamine7 receptor binding sites in rat hypothalamus: Sensitivity to chronic antidepressant treatment. Mol Pharmacol. 1995;47:99-103.
15. Mullins UL, Gianutsos G, Eison AS. Effects of antidepressants on 5-HT7 receptor regulation in the rat hypothalamus. Neuropsychopharmacology. 1999;21:352-367.
16. Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL. Amisulpride is a potent 5-HT7 antagonist: Relevance for antidepressant actions in vivo. Psychopharmacology (Berl). 2009;205:119-128.
17. Kvachnina E, Liu G, Dityatev A, et al. 5-HT7 receptor is coupled to G alpha subunits of heterotrimeric G12-protein to regulate gene transcription and neuronal morphology. J Neurosci. 2005;25:7821-7830.
18. Dalmau A, Bergman B, Brismar B. Somatic morbidity in schizophrenia a case control study. Public Health. 1997;111:393-397.
19. Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry. 1998;173:11-53.
20. Kurzthaler I, Fleischhacker WW. The clinical implications of weight gain in schizophrenia. J Clin Psychiatry. 2001;62 Suppl 7:32-37.
21. Allison DB, Casey DE. Antipsychotic-induced weight gain: A review of the literature. J Clin Psychiatry. 2001;62 Suppl 7:22-31.
22. Allison DB, Mackell JA, McDonnell DD. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv. 2003;54:565-567.
23. Werneke U, Taylor D, Sanders TA. Options for pharmacological management of obesity in patients treated with atypical antipsychotics. Int Clin Psychopharmacol. 2002;17:145-160.
24. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res. 2004;66:51-57.
25. de Hert MA, van WR, van ED, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res. 2006;83:87-93.
26. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80:19-32.
27. Bai YM, Chen JY, Yang WS, et al. Adiponectin as a potential biomarker for the metabolic syndrome in Chinese patients taking clozapine for schizophrenia. J Clin Psychiatry. 2007;68:1834-1839.
28. Buis W. Patient's opinions concerning side effects of neuroleptics. Am J Psychiatry. 1992;149:844-845.
29. Casey D. Side effect profiles of new antipsychotic agents. J Clin Psychiatry. 1996;57:40-45.
30. Kerwin RW. The new atypical antipsychotics. A lack of extra pyramidal side-effects and new routes in schizophrenia research. Br J Psychiatry. 1994;164:141-148.
31. Kane JM. Clozapine in the treatment of schizophrenia. Encephale. 1996;22:7-11.
32. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical antipsychotic trials of intervention effectiveness (CATIE) investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1203.
33. Colonna L, Saleem P, Dondey-Nouvel L, Rein W. Long term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Int Clin Psychopharmacol. 2000;15:13-22.
34. Carrière P, Bonhomme D, Lemperière T. Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia. Eur Psychiatry. 2000;15:321-329.
35. Peuskens J, Bech P, Möller HJ, Bale R, Fleurot O, Rein W. Amisulpride versus risperidone in the treatment of acute exacerbations of schizophrenia. Psychiatry Res. 1999;88:107-117.
36. Sechter D, Peuskens J, Fleurot O, et al. Amisulpride vs risperidone in chronic schizophrenia: Results of a 6-month double-blind study. Neuropsychopharmacology. 2002;27:1071-1081.
37. Martin S, Ljo H, Peuskens J, et al. A double-blind, randomized comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: Short-term results at two months. Curr Med Res Opin. 2002;18:355-362.
38. Mortimer A, Martin S, Loo H, et al. A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Int Clin Psychopharmacol. 2004;19:63-69.
39. Leucht S, Wagenpfeil S, Hamann J, et al. Amisulpride is an atypical antipsychotic associated with low weight gain. Psychopharmacology (Berl). 2004;173:112-115.
40. Tandon R. Section of Pharmacopsychiatry; World Psychiatric Association. World Psychiatric Association Pharmacopsychiatry Section. Schizophr Res. 2008:100;20-38.
41. Motlová L. Are there any differences in the efficacy among second generation antipsychotics in the treatment of schizophrenia and related disorders? Ann Clin Psychiatry. 2007;19:133-143.
42. American Psychiatric Association, 2008. Practice guidelines for the treatment of patients with schizophrenia. Available from: http://www.psychiatryonline.com/pracGuide/pracGuideChapToc_6.aspx. Accessed Jul 29, 2010.
43. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs. 2005:19 Suppl 1:1-93.
44. Lin CC, Bai YM, Wang YC, et al. Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics. J Clin Psychopharmacol. 2009;29:529-536.
45. Rettenbacher MA, Ebenbichler C, Hofer A, et al. Early changes of plasma lipids during treatment with atypical antipsychotics. Int Clin Psychopharmacol. 2006;21:369-372.
46. Lecrubier Y. Amisulpride: Progress and outcomes. Curr Med Res Opin. 2002;18 Suppl 3:18-22.
47. Saleem P, Olié JP, Loo H. Social functioning and quality of life in the schizophrenic patient: Advantages of amisulpride. Int Clin Psychopharmacol. 2002;17:1-8.
48. Weiden P, Aquila R, Standard J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry. 1996;57 Suppl 11:53-60.
49. Franz M, Lis S, Pluddemann K, Gallhofer B. Conventional versus atypical neuroleptics: Subjective quality of life in schizophrenic patients. Br J Psychiatry. 1997;170:422-425.
50. Coulouvrat C, Dondey-Nouvel L. Safety of amisulpride (Solian): A review of 11 clinical studies. Int Clin Psychopharmacol. 1999;14:209-218.
51. de Oliveira IR, Juruena MF. Treatment of psychosis: 30 years of progress. J Clin Pharm Ther. 2006;31:523-534.